Find Clinical Trials

Inclusion Criteria: * PH group: When the mean pulmonary artery pressure is greater than 25mmHg at rest or greater than 30mmHg during exercise. * Signed informed consent obtained prior to participations with the ability to comply with protocol and be available for study visits over 5 years. Exclusion Criteria: * Acute exacerbation in the past 3 months Having other respiratory diseases with massive lung tissue destruction such as severe bronchiectasis and tuberculosis, etc. * Serious uncontrolled diseases thoracic or abdominal surgery in the last 3 months. * Eye surgery in the last three months. * Retinal detachment myocardial infarction in the last 3 months. * Admission to hospital for any cardiac condition in the last month. * Heart rate over 120 beats per minute. * Antibacterial chemotherapy for tuberculosis pregnant or breast feeding.

Inclusion Criteria: * Age at least 18 years * Undergoing major surgery under general anesthesia * Expected surgery time \>2 h * Expected length of postoperative stay \>2 d * Invasive blood pressure (radial or femoral) and Mostcare monitoring * Indication for a passive leg raising test: risk of hypovolemia (preoperative fasting, bowel preparation, loss of appetite, limited access to water) or expected major surgery, expected blood loss, cardiovascular comorbidity (hypertension, diabetes mellitus, coronary artery disease, peripheral artery disease, hyperlipidemia, morbidity, active smoking). * Recruitment after booking for surgery with sufficient time to read, understand and question study patient information prior to attending for surgery. * Ability and willingness to provide informed consent Exclusion Criteria: * Refuse to consent to the study * Arterial wave form distortion * Cardiac arrhythmia * Inappropriate identification of the dicrotic notch for any reason * Planned intraoperative mean arterial blood pressure \< 65 mmHg * Hemodynamic instability defined as mean arterial blood pressure \< 65 mmHg * Preoperative requirement of inotrope/vasopressor infusion * Preoperatively receiving vasoactive drugs * Patients fitted with an intra-aortic balloon pump * Patients fitted with Extracorporeal Membrane Oxygenation * Critically ill patients requiring preoperative intensive care unit * Presence of intraabdominal hypertension * New York Heart Association Class 3-4 heart failure * Congestive heart failure with ejection fraction \< 35% * Glomerular filtration rate \< 30 ml/min/1.73 m2 * Ongoing renal replacement therapy

Inclusion Criteria: 1. Adults age ≥ 18 inclusive at the time the Informed Consent Form (ICF) is signed. 2. Histologically proven, metastatic or advanced epithelial cancer including the following cancer types: 1. Urothelial 2. Cervical 3. Ovarian epithelial 4. Triple-negative breast 5. HR+/HER2- breast 6. Pancreatic ductal adenocarcinoma 7. Gastric adenocarcinoma 8. Esophageal carcinoma 9. Non-small cell lung 10. Colorectal 3. Progressive disease at baseline, refractory or relapsed to standard of care or who have declined standard therapy. 4. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria v 1.1. 5. Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1. 6. Life expectancy of \> 12 weeks. 7. Echocardiogram (ECHO) or multiple gated acquisition scan showing an ejection fraction greater than or equal to 50%. 8. Electrocardiogram (ECG) showing no clinically significant abnormality at Screening or showing an average QTc interval \< 450 msec in males and \< 470 msec in females (\< 480 msec for participants with bundle branch block). Either Fridericia's or Bazett's formula may be used to correct the QT interval. 9. Oxygen saturation of greater than or equal to 90% on room air measured by pulse oximetry. 10. Adequate organ function as defined by laboratory values at Screening. 11. Willing and able to provide written informed consent. 12. Willing to perform and comply with all study procedures including undergoing study-related biopsies and attending clinic visits as scheduled. 13. Men must abstain from sperm donation during study treatment or for 4 months following last dose of study treatment. 14. Men and WOCBP must be willing to practice a highly effective method of contraception. Exclusion Criteria: 1. Known active CNS metastasis and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression for at least 4 weeks by repeat imaging), clinically stable, and without requirement of steroid treatment for at least 14 days prior to the first dose of study intervention. 2. Pregnant or nursing women. 3. Must be \> 28 days beyond major surgery, including hepatectomy or joint replacement. 4. Prior allogeneic bone marrow transplantation or solid organ transplant. 5. Spinal cord compression not definitively treated with surgery and/or radiation. 6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. 7. Any acute illness including fever (\> 100.4° F or \> 38° C) within 7 days prior to Day 1 8. Active systemic bacterial, fungal, or viral infection within 7 days prior to Day 1. Participant cannot have tested positive for COVID-19 within 7 days prior to Day 1. 9. Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV). 10. Other primary malignancies, except: 1. Adequately treated basal cell or squamous cell carcinoma 2. In situ carcinoma of the cervix or bladder, treated curatively and without evidence of recurrence for at least 2 years prior to the study, or 3. A primary malignancy which has been completely resected and in complete remission for at least 2 years 11. History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. 12. Prior grade \> 3 immune-related AEs such as pneumonitis, colitis, hepatitis, nephritis; prior dermatitis and endocrinopathies are allowed provided corticosteroids are no longer required and endocrine-replacement therapy is stable and discontinued from prior therapy. 13. Active autoimmune disease not related to prior therapy for primary malignancy that has required systemic therapy in the last 1 year. 14. History of symptomatic congestive heart failure (New York Heart Association classes II-IV) or serious active arrhythmias or other clinically significant cardiac disease within 12 months of enrollment. 15. Toxicity from previous anti-cancer therapy defined as toxicities (other than alopecia, or laboratory values listed above) not yet resolved to NCI CTCAE v5.0 Grade ≤ 1 or baseline. Participants with chronic Grade 2 toxicities (eg, peripheral neuropathy, laboratory values) may be eligible per the discretion of the Investigator and Medical Monitor. 16. Has received: 1. Radiotherapy within 2 weeks of first administration of MT-302 2. Cytotoxic chemotherapy for treatment of the primary malignancy within 28 days or 5 half-lives, whichever is shorter, of administration of MT-302 3. Immune therapy for primary malignancy (eg, monoclonal antibody therapy, checkpoint inhibitors) within 28 days or 5 half-lives, whichever is shorter of first administration of MT-302 4. Targeted therapies for primary malignancy within 28 days or 5 half-lives, whichever is shorter, of first administration of MT-302 5. Anti-cancer vaccine within 12 weeks of first administration of MT-302 6. COVID-19 mRNA vaccine within 6 weeks of first administration of MT-302 17. Has received a live vaccine ≤ 6 weeks prior to first administration of MT-302 18. Has received packed red blood cells or platelet transfusion within 2 weeks prior to first administration of MT-302 19. History of an allergic reaction to any of the excipients 20. Enrollment in another interventional clinical trial within 28 days or 5 half-lives of the drug, whichever is shorter, of first administration of MT-302 21. Any other condition that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with the study requirements.

Inclusion criteria (Participants must…) * Have a diagnosis of prostate cancer or breast cancer * Be undergoing hormone therapy (e.g., androgen deprivation therapy) * Be 55 years old or older * Speak and/or read English Exclusion criteria (Participants must not…) * Be on active chemotherapy or radiation for cancer * Be underweight (≤18.5 kg/m2) * Have lost more than 10 pounds unintentionally in the last 12 months * Have surgery planned during the study duration * Have had a major surgery, including hip/knee surgery, in the last 3 months * Have documented advanced liver, heart, or lung disease * Have any contraindications to the proposed nutrition intervention as identified by their medical provider, their designee, or the study team (e.g., type 1 diabetes, risk for hypoglycemia, medication requirements, recent history of an eating disorder, on artificial nutrition) * Already eat all their food in a window that is 10 h or shorter on most (6/7) days of the week

Inclusion Criteria: 1. Histopathologically proven patients of breast or oral cavity SCC 2. Age \> 18 and \< 65 3. Operable cancers planned to undergo upfront curative surgery 4. Patient fit for surgery (ASA Grade I / II) 5. Patient Voluntarily willing to give consent for study Exclusion Criteria: 1. Planned for any other pre or peri-operative intervention such as neoadjuvant chemotherapy or targeted therapy or radiation 2. Presence of medical disease such as pulmonary, renal, liver, gastro-intestinal disease which may interfere with any study specific procedure (deranged renal parameters \> 1.5 times normal range or deranged liver function tests such as \> 2.5 times raised liver enzymes) 3. History of substance abuse (including cannabis-related products) or alcohol abuse 4. Personal history of psychiatric disease or Significant family history of psychiatric disease 5. Pregnancy and/or lactation 6. Patients currently (within last 14 days before consenting) on other CNS depressants such as alcohol, barbiturates, benozodiazapines (like diazepam, alprazolam etc) 7. Patients on other medications which will likely have a drug interaction with cannabis- such as clozapine, duloxetine, naproxen, cyclobenzaprine, olanzapine, haloperidol, and chlorpromazine, macrolides, calcium channel blockers, benzodiazepines, cyclosporine, sildenafil (and other PDE5 inhibitors), antihistamines, haloperidol, antiretrovirals 8. Any other illness or abnormal laboratory investigations which the investigator considers as making the patients ineligible for the study 9. Any patient with positive HIV, HBsAg, HCV status

Inclusion Criteria: 1. Women aged 18-70 years old; 2. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score 0 or 1; 3. Expected lifetime of not less than three months; 4. Disease-free interval \>6 months； 5. Adequate tumor tissue samples collected within a time frame of less than 3 months; 6. Histological results recorded as TNBC \[negative HER2, ER, and progesterone receptor (PgR) status\] and LAR subtype according to the classification of Fudan University Shanghai Cancer Center (FUSCC); 7. Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); 8. Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resected; 9. Adequate hematologic and end-organ function, laboratory test results; 10. Within the 3 weeks prior to study initiation, patients have not received radiotherapy, endocrine therapy, targeted therapy, or surgery, and have recovered from acute toxicities associated with previous treatments (if surgery was performed, wound healing is complete); no peripheral neuropathy or grade I peripheral neurotoxicity. 11. Female subjects with fertility are required to use a medically approved contraceptive method during the study treatment； 12. Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up. Exclusion Criteria: 1. Use of radiotherapy (except for palliative reasons), chemotherapy, and immunotherapy in the 3 weeks prior to treatment, excluding bisphosphonates (which can be used for bone metastasis)； 2. History of clinically uncontrolled heart disease, including congestive heart failure, angina, myocardial infarction within the past 6 months, or ventricular arrhythmias； 3. Common Terminology Criteria for Adverse Events (CTCAE) grade ≥1 adverse reactions attributed to previous treatments； 4. Underwent major surgery (excluding outpatient minor procedures, such as placement of vascular access) within the first 3 weeks of the investigational treatment； 5. Pregnant or lactating patients； 6. History of malignancy within the past five years (excluding cured basal cell carcinoma and cervical carcinoma in situ)； 7. Presence of third-space fluid accumulation (such as significant pleural effusion and ascites) that cannot be controlled by drainage or other methods； 8. Non-infectious interstitial lung disease (ILD) or non-infectious pneumonia requiring steroid hormone therapy, current ILD/non-infectious pneumonia, or suspected ILD/non-infectious pneumonia that cannot be ruled out by imaging examinations during screening (Note: Subjects found to have ILD/non-infectious pneumonia during baseline screening chest CT are ineligible)； 9. Known active Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection or HBV DNA ≥500, or patients with chronic phase accompanied by abnormal liver function； 10. Individuals with allergies or a history of known allergy to components of the study drugs or other monoclonal antibodies； 11. History of immunodeficiency, including HIV-positive test results, acquired or congenital immunodeficiency diseases, or history of organ transplantation. Positive syphilis antibody test； 12. According to the investigator's judgment, any evidence of diseases that the investigator considers unfavorable for the subject's participation in the study or that may affect their adherence to the protocol.

Inclusion Criteria: 1. In- or outpatients, at least 18 years of age up until 65. 2. Being willing and able to provide written informed consent. Having a legal guardian to cosign is allowed. Informed consent will be signed at visit 1, before any study procedure. 3. Female subjects of child bearing potential must use effective contraception during the trial as per the requirements of the applicable SmPCs and should have a negative pregnancy test at visit 1 or 2 (before randomisation). 4. Meeting diagnostic criteria for a primary diagnosis of major depressive disorder (without psychotic features), according to DSM-5. The primary diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). 5. Subject experiences a treatment failure due to lack of efficacy in the current episode, as confirmed by a CGI-I ≥3; perferably, this treatment is a first-line pharmacotherapeutic agent for the primary DSM-5 diagnosis, and was prescribed for at least 4 weeks within an effective dose range as specified in the Summary of Product Characteristics (SmPCs). 6. Subject and clinician intend to change pharmacotherapeutic treatment. However, other lines of treatment are allowed as well. 7. A minimum symptom severity threshold needs to be present (moderate level; see below) and subject needs to experience functional impairment. * The minimum symptom severity threshold is a score of ≥20 on the Montgomery Åsberg Depression Rating Scale (MADRS) * Functional impairment is defined as a score of 5 or higher on any of the three scales of the Sheehan Disability Scale (SDS). Exclusion criteria: 1. Being pregnant or breastfeeding. 2. Subject has used (es)ketamine previously for the treatment of depressive symptoms. 3. Subject has a known intolerance to (es)ketamine or to all TAU medication. 4. Meeting any of the contraindications for (es)ketamine, or to all TAU medication options, as specified within the applicable SmPC, supported by clinically significant abnormal values on local laboratory tests, electrocardiogram (ECG) or physical examinations. 5. Subject has participated in another clinical trial in which the subject received an experimental or investigational drug or agent within 30 days before visit 1. 6. Subject experiences any other significant disease or disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the trial, or may influence the result of the trial, or the subject's ability to participate in the trial. 7. Subjects with active suicidal ideation with some intent to act, without specific plan ("Yes" to question 4 of the Columbia-Suicide Severity Rating Scale (C-SSRS)) or active suicidal ideation with specific plan and intent ("Yes" to question 5 of the C-SSRS), followed by an assessment by the treating clinician who determines it is not safe for the subject to participate in the study 8. Subject meets criteria for current substance use disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is allowed, as well as mild and moderate alcohol and/or cannabis use disorder (as defined by MINI v7.0.2). Severe alcohol and/or cannabis use disorder are not allowed. 9. Subjects have not been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities. 10. Subjects dependent on the sponsor, investigator or trial site must be excluded from participation in advance.

Inclusion Criteria: * Written informed consent * Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy. * Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines): * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Chronic lymphoproliferative disorder of NK cells * Aggressive NK-cell leukemia * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood * Chronic active EBV infection of T- and NK-cell type, systemic form * Hydroa vacciniforme-like lymphoproliferative disorder * Adult T-cell leukemia/lymphoma * Extranodal NK/T-cell lymphoma, nasal type * Enteropathy-associated T-cell lymphoma * Monomorphic epitheliotropic intestinal T-cell lymphoma * Intestinal T-cell lymphoma, not otherwise specified (NOS) * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract * Hepatosplenic T-cell lymphoma * Subcutaneous panniculitis-like T-cell lymphoma * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy) * Sézary syndrome * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy) * Primary cutaneous Gamma-Delta T-cell lymphoma * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy) * Peripheral T-cell lymphoma, not otherwise specified * Angioimmunoblastic T-cell lymphoma * Follicular T-cell lymphoma * Nodal peripheral T-cell lymphoma with TFH phenotype * Anaplastic large cell lymphoma, ALK-positive * Anaplastic large cell lymphoma, ALK-negative * Breast-implant associated anaplastic large cell lymphoma. * NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy. Exclusion Criteria: * Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy. * Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Inclusion Criteria: * All children between ages 5-\<18 years * All children with voluntary assent/consent and parent's permission Exclusion Criteria: * circumstances interfere with the participant's ability to give informed consent (diminished understanding or comprehension, or any language barriers that may pose potential risk in participation under false expectations) * randomly selected children who choose not to participate (lack of assent/consent), even if parent's permission was received, * conditions that interfere with a patient's ability to follow study guidelines, e.g., the use of drugs, alcohol or tobacco products * ages \>18 years or under 5 years * Children will be excluded from the analysis for the determination of normative reference values for blood pressure and anthropometry if taking certain concomitant medication(s) that may affect their blood pressure, or any underlying disease e.g., chronic kidney disease, chronic heart disease etc. that may raise blood pressure.

Inclusion Criteria: * Women and Men; ≥18 years at the time of screening (or per national guidelines) * Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with absence of any evidence of metastatic disease as defined in the protocol. * Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy. * Patients must be randomised within 12 months of definitive breast surgery. * Patients may have received up to 12 weeks of endocrine therapy prior to randomisation. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 * Adequate organ and bone marrow function Exclusion Criteria: * Inoperable locally advanced or metastatic breast cancer * Pathological complete response following treatment with neoadjuvant therapy * History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered a very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation * Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance " * Known LVEF \<50% with heart failure NYHA Grade ≥2. * Mean resting QTcF interval \> 480 ms at screening * Concurrent exogenous reproductive hormone therapy or non topical hormonal therapy for non-cancer-related conditions * Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors ( eg, denosumab) * Previous treatment with camizestrant, investigational SERDs/investigational ER targeting agents, or fulvestrant * Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding. * Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists that would preclude the patient from receiving any LHRH agonist.

Inclusion Criteria: * Age between 18 and 65. * Diagnosis of unipolar or bipolar depression (seasonal or non-seasonal) as assessed with the Mini-International Neuropsychiatric Interview (M.I.N.I.) * A current depressive episode (a score of 6 or higher on the Quick Inventory of depressive symptomatology Self Report (QIDS-SR) * Sufficient knowledge of Dutch or English language to fill in questionnaires * Provided Informed consent Exclusion Criteria: * A current (hypo)manic or mixed episode (as assessed with the M.I.N.I.) * Current psychotic episode (as assessed with the M.I.N.I.) * Prominent active suicidality (score 10 or higher on the M.I.N.I. module) * Antidepressant therapy (medication, psychotherapy or BLT, or other forms of specific treatments for depression) that started less than 2 months prior to study entry * participants with bipolar disorder should be in mood-stabilizing treatment for at least 1 month in a recommended dosage, * Use of melatonin or agomelatine in the last month * Current use of antibiotics * Current use of light sensitivity increasing medication * Travelled across more than 1 time zone during past month or during the treatment * Travelled to sunny holiday locations/winter sports during past month * pre-existing eye and skin disorders (retinitis pigmentosa, porphyria, chronic actinic dermatitis and sun-induced urticaria) * Systemic disorders with potential retinal involvement (rheumatoid arthritis and systemic lupus erythematosus) * Suffering from colour blindness (assessed by Ishihara colour plates) * Participated in night shift work in the last three months * (Retinal) blindness, severe cataract and glaucoma * Light-induced migraine or epilepsy * Pregnancy, or parents with a child younger than 18 months old

Inclusion Criteria: * Patients aged ≥18 years and ≤75 years;Patients aged ≥18 years and ≤75 years; * Her2-positive invasive breast cancer confirmed by pathological examination met the following conditions: Positive HER2 expression: Immunohistochemical staining (IHC) showed positive HER2 3+ and/or fluorescence in situ hybridization (FISH); Tumor staging: inoperable locally advanced or recurrent metastatic breast cancer; Patients with local recurrence must be confirmed by the investigator to be unable to undergo radical surgical excision. * At least one measurable lesion was present according to RECIST1.1 criteria; * The ECOG score is 0 to 1; * No systematic antitumor therapy (except first-line endocrine therapy) has been received at the locally advanced stage (clinically inoperable) or at the stage of recurrence and metastasis; * The functional level of major organs must meet the following requirements (no blood transfusion within 2 weeks prior to screening, no use of leukocyte enhancing and platelet enhancing drugs) : 1. Blood routine: neutrophils (ANC) ≥1.5×109/L; Platelet count (PLT) ≥90×109/L; Hemoglobin (Hb) ≥90 g/L; 2. Blood biochemistry: total bilirubin (TBIL) ≤ upper limit of normal value (ULN), known patients with Gilbert syndrome, TBIL≤2×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×ULN, patients with liver metastasis required ALT and AST≤5×ULN; Alkaline phosphatase ≤2.5×ULN; Urea/urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN; 3. Cardiac ultrasound: left ventricular ejection fraction (LVEF) ≥50%; 4. 12-lead electrocardiogram: Fridericia corrected QT interval (QTcF) \<470 msec; * Expected survival ≥3 months; * Participate in this study voluntarily, sign informed consent, have good compliance and be willing to cooperate with follow-up. Exclusion Criteria: * Known allergic history of drug components of the program; * Patients judged unsuitable for systematic chemotherapy by researchers; * Use of endocrine therapy drugs within 14 days before baseline; * Patients with only bone or skin as target lesions; * Other malignancies, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or squamous cell carcinoma, within the previous 5 years; * Peripheral neuropathy ≥ grade 3 according to CTCAE 5.0 criteria; * Had received major surgical procedures or significant trauma within 4 weeks prior to randomization, or was expected to receive major surgical treatment; * Serious heart disease or discomfort, including but not limited to: heart failure or contraction dysfunction (LVEF \<50%) past medical history high risk or the need for treatment of angina or arrhythmia (such as second degree atrioventricular block type 2 or 3 degree atrioventricular block, ventricular tachycardia) clinical significance of heart valve disease ECG showed wall permeability myocardial infarction poorly controlled hypertension, systolic blood pressure\>150 mmHg and/or diastolic blood pressure\>100 mmHg * Dysphagia, chronic diarrhea, intestinal obstruction and other factors affecting drug delivery and absorption; * A history of immunodeficiency, including HIV infection, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation; * Participated in other drug clinical studies within 4 weeks prior to screening; * There is a third interstitial effusion (such as pleural fluid and ascites) that cannot be controlled by drainage or other methods; * Pregnant or lactating women, women of childbearing age who are unable to take effective contraceptive measures throughout the trial period; * Have a serious concomitant disease or other co-medical condition that interferes with planned treatment or any other condition that is not suitable for participation in the study, such as active hepatitis B, lung infection requiring treatment, etc.

Inclusion Criteria: * Adults age 18-65 * A current diagnosis of major depressive disorder according to DSM-5 criteria per MINI interview * Moderate to severe level of current depressive symptoms (MADRS score ≥20) * Failure of at least one adequate trial of antidepressant medication (defined as: therapeutic doses of antidepressant medication for ≥ 6 weeks) * No adverse reactions to ketamine * Capacity to consent and comply with study procedures, including sufficient proficiency in English Exclusion Criteria: * Meets DSM-5 criteria for bipolar disorder, schizophrenia, any psychotic illness, including substance-induced psychosis, active PTSD, dissociative disorders and current substance-induced mood disorder, OCD, eating disorder, panic disorder. * Suicide attempt in the past 4 weeks or current risk of suicide * Current alcohol or drug substance use disorder according to DSM-5 * Cognitive- or intellectual impairments which would interfere with participation in MBCT or assessments including meeting criteria for Delirium, Dementia, Amnesia, Cognitive Disorders, * Personality Disorders (borderline, antisocial, paranoid, schizoid, histrionic) that may interfere with treatment * Previous participation in MBCT or MBSR group * Pregnant or planning to become pregnant during the study period * Heart disease as indicated by history, abnormal ECG, previous cardiac surgery. * Hypertension (\>160/100) * Unstable physical disorders which might make participation hazardous such as history of AIDS, known lab abnormalities, active hepatitis or other liver disease with elevated transaminase levels (\< 2-3 X upper limit of normal will be considered acceptable if PT/PTT is normal), renal failure (creatinine \> 2, BUN \>40), or untreated diabetes. * Previous history of ketamine misuse or abuse, or a history of an adverse reaction/experience with prior exposure to ketamine * BMI \> 32 * History of documented obstructive sleep apnea * On psychotropic or other medications whose effect could be disrupted by participation in the study or not allowed during the study (such as monoamine oxidase inhibitors). * Patient unable or unlikely to comply with the study protocol or for any other conditions that might indicate that the patient is unsuitable for the study as judged by the investigator * Positive urine drug screen, except for marijuana or benzodiazepine if prescribed.

Inclusion Criteria: * Age: * Breast screening \> 40 * Lung screening 50-80 * Male (M) or Female (F) * Current, former, or never smokers * Close family or friend with smoking history (in or out of state) Exclusion Criteria: * Age: * Breast screening \< 40 * Lung screening \< 50 or \> 80 * Persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded * Persons with an active cancer

Inclusion Criteria: * Males and females over the age of 18 years * With or without symptoms of depression * Physically inactive or sedentary (less than 30 minutes per day) * Normal vision and no color blindness * No physical disorders such as walking with assistance Exclusion Criteria: * Below the age of 18 years or over 65 years, * Women who are pregnant * Individuals who have been diagnosed with mental disorders * Individuals with leg injuries * Individuals with cardiac problems * Individuals with a history of asthma * Individuals with a body mass index over 30.

Inclusion Criteria: * Patients over the age of 12 with ACL injuries undergoing ACLR with a Henry Ford Sports Orthopedic Surgeon * First time ACLR on the injured knee Exclusion Criteria: * Patients undergoing revision ACL surgery * Concomitant posterior cruciate ligament injury of the involved knee * Systemic or local infection pre-operatively * Systemic administration of any type of corticosteroid or immunosuppressive agents within 30 days of surgery * History of rheumatoid arthritis, inflammatory arthritis, or autoimmune diseases * Pregnancy

Inclusion Criteria: * Subjects must have histologically or cytologically confirmed axillary node positive unilateral breast cancer and may be female or male. * Subjects must have received no prior surgical interventions to the axilla except for core needle biopsy or sentinel node biopsy within 30 days of the planned axillary node dissection. * Age \>18 years. Children are excluded from this study since breast cancer is quite rare in children. * ECOG Performance status 0 or 1 * Subjects must have normal organ and marrow function as defined below: * Leukocytes ≥ 3,000/mcL * Absolute neutrophil count ≥ 1,500/mcL * Platelet count ≥ 100,000/mcL * Total bilirubin within normal institutional limits * AST (SGOT) ≤ 2.5 X institutional upper limit of normal * ALT (SGPT) ≤ 2.5 X institutional upper limit of normal * Serum Creatinine within normal institutional limits * Subjects must have at least one suitable lymphatic and one suitable vein amenable to lymphovenous bypass anastomosis. * Subjects must have the ability to understand and the willingness to sign a written informed consent document. * Patients may be treated with adjuvant or neoadjuvant therapies at the discretion of the treating medical oncologist * Patients may be treated with adjuvant radiation therapy at the discretion of the treating radiation oncologist. * Patients may be treated with either mastectomy or breast conserving surgery at the discretion of the treating surgical oncologist. * In order to complete the Lymph-ICF-UL questionnaire, participants must be able to speak and/or read English. * Healthy controls include women aged 18-75 without a current or past history of breast cancer or lymphedema who are willing to undergo blood draw. Exclusion Criteria: * Contraindication to ICG as a) iodine hypersensitivity, b) renal failure, c) uremia and d) on dialysis. * Subjects receiving any prior surgical treatment or radiation to the axilla prior to protocol enrollment (except sentinel node biopsy within the past 30 days). * Subjects with known regional cervical or supraclavicular nodal disease or distant metastatic disease. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to isosulfan blue dye or other agents used in this study. * History of pre-existing lymphedema or measured lymphedema at baseline upon study enrollment * BMI greater than or equal to 40. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * History of pulmonary embolism or deep venous thrombosis * Patients must not be on anticoagulant therapy with warfarin, clopidogrel (Plavix), apixavan (Eliquis), heparin, low molecular weight heparin, rivaroxaban (Xarelto), ticlodipine (Ticlid), fonduparinux (Arixtra) with the exception of routine heparin flushes to a portacath. * Patients treated with sentinel lymph node biopsy only without ALND * Arteriovenous fistula or the presence of an indwelling peripherally inserted central catheter (PICC line), or the presence of a central venous line or portacath in the ipsilateral arm. * ECOG performance status of 2 or higher. * Pregnant or breast-feeding women are excluded from the study given that it is unknown whether isosulfan blue can cause fetal harm and it is desirable to limit anesthesia time in this population * Less than 18 years of age or greater than 75 years of age.

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Male\* or female, aged 18 to 60 years, inclusive 3. In good general health as evidenced by medical history 4. Females of childbearing potential agree to use an accepted method of contraception (see below) throughout study participation and for 120 days after study drug infusion. 5. Males sexually active with a female partner must agree to use a condom with spermicide for 120 days after study drug infusion or be surgically sterile for at least 90 days before screening. Males must also agree to not donate sperm for 120 days after study drug administration. 6. Agreement to adhere to Lifestyle Considerations throughout study duration 7. Ability of subject to understand and the willingness to sign a written informed consent document. * Enrollment of healthy male subjects will be limited to no more than 14 out of the total study cohort of 32 in order to ensure an adequate representation of female subjects. Accepted methods of contraception for females of childbearing potential: * Use of an implanted or intrauterine hormonal device for at least 30 consecutive days before study drug infusion * Use of oral, patch or injectable contraceptives or a vaginal hormonal device for at least 30 consecutive days before study drug infusion * Use of a non-hormonal intrauterine device for at least 30 consecutive days before study drug infusion * Two barrier methods such as a diaphragm with spermicide or a condom with spermicide EXCLUSION CRITERIA: An individual who meets any of the following criteria prior to informed consent will be excluded from participation in this study: 1. Pregnancy or lactation. Females of childbearing potential must have a negative serum Beta-human chorionic gonadotropin test no more than 48 hours from study drug infusion. 2. A history of human immunodeficiency virus (HIV) infection. 3. History of severe drug or excipient allergy or hypersensitivity 4. Known allergy to any of the components of the investigational drug or placebo 5. Recent infection or febrile illness within the past 14 days 6. Treatment with another investigational drug within the past 30 days or 5 half-lives, whichever is longer 7. Any vaccination within the past 4 weeks or receipt of a live-attenuated vaccine within the past 6 months 8. Use of tobacco products within the past 3 months 9. Illicit drug use (e.g. cocaine, opioids, methamphetamine, PCP) within the past 6 months or positive urine drug screen at Screening Visit 10. Marijuana (cannabis) use within the past 30 days or positive urine drug screen at Screening Visit 11. History of alcohol abuse within the past 2 years 12. Current clinically significant medical illness that is uncontrolled despite appropriate medical treatment including (but not limited to) hematologic, oncologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, infectious, hepatic, dermatologic, psychiatric, neurologic, autoimmune or allergic disease 13. Body mass index less than 17 or greater than 32 kg/m\^2 14. Clinically significant abnormal results on clinical blood testing completed at the Screening Visit 15. Electrocardiographic evidence of clinically relevant heart disease 16. Diabetes mellitus requiring medical treatment 17. Received another monoclonal antibody in the past 30 days 18. Use of herbal supplements, or similar products within the past 2 weeks 19. Blood donation equal to or above 500 mL within 2 months prior to dosing. 20. Any other finding that, in the judgment of the Investigator, would increase the risk of having an adverse outcome from participating in the study. Justification to exclude minors: Given that the vast majority of patients with PAH are \>18 years of age and the fact that this is a first in human study, the risks of including children/minors (ie. subjects \< 18 yrs of age) are not justified given the limited potential benefits of including these subjects. Justification to exclude adults \>60 years old: Subjects \> 60 years of age are more likely to have comorbid medical conditions that could place them at increased risk of participation.

Inclusion Criteria: 1. Age 30-65y old at the time of enrollment 2. Non-institutionalized 3. Living in PR at the time of recruitment and for at least the previous year and not planning to move from the island within the next 3 years 4. Able to answer questions without assistance 5. Having a cellphone with the capacity to receive text messages and be willing to receive daily text messages from the study on the designated cellphone number 6. Having at least one of the following: 1. elevated BMI 2. elevated waist circumference 3. self-reported physician-diagnosed hypertension or use of hypertension medication or measured high blood pressure at the baseline visit 4. self-reported physician-diagnosed pre-diabetes or measured pre-diabetes at the baseline visit 5. self-reported physician-diagnosed dyslipidemia or use of lipid-lowering agents or laboratory values confirming dyslipidemia Exclusion Criteria: 1. Under 30 or over 65 years of age (on the day of the interview). 2. Currently not living in Puerto Rico or not lived on the island for at least 1 year or planning to move within 3 years 3. Institutionalized 4. Not able to answer questions without assistance 5. Not having at least 1 of the five listed metabolic criteria 6. Self-reported physician-diagnosed type 1 or type 2 diabetes or use of diabetes medication (including insulin) or diabetes-diagnosis values confirmed by laboratory 7. Self-reported pregnancy 8. Gastrointestinal or chronic condition that would impact eating behaviors or nutritional status 9. Intolerance or allergies to legumes (i.e.: beans and nuts), vegetable oils (i.e.: corn, olive, canola), or fresh produce 10. Living with another person participating in the study 11. Participating in another research study that conflicts with PRECISION

Inclusion Criteria: * Primary diagnosis of MDD as assessed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (SCID-5) * Total score of 20\* or above on the BDI-II (cut-off score for moderate depression) (Beck et al., 1996). (\*Based on previous research by Brewin et al. (2009) \& Yuen-tin (2017) demonstrating averages of BDI-II: 34-35, in their population.) * Age 18-65 * Dutch or English as a first language (or estimated as sufficient to receive treatment in either of these languages without interpreter) * Willingness to participate in the study (signed informed consent) Exclusion Criteria: * DSM-5 Bipolar disorder, type 1 (current or past); if there has been no manic episode the last year patients will be included * Psychotic disorders (though psychotic features alongside depression will be allowed) * Organic brain disease * Intelligence Quotient (IQ) \< 80 * High risk of self-harm or suicide * Current substance abuse severe level * Start of new medication within 2 months before beginning the study (medication used for longer periods can be continued; patients are requested to keep medication stable during the course of the study) * Having received ImRs (either as a stand-alone or embedded in a greater treatment such as cognitive behavior therapy (CBT) or schema therapy) within the last year * No other evidence-based treatment of MDD is allowed during the study. * Not able to plan enough time for weekly therapy sessions (45-60 minutes); weekly measurements (estimate of 5 minutes) and other measurements (estimate of 20 minutes); and the qualitative post-treatment interview (estimate of 60 minutes) during the study period.